Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Estetrol is a synthetic estrogen and a naturally occurring steroid hormone produced only during pregnancy by the fetal liver. It is used primarily in combination with drospirenone as an oral contraceptive to prevent pregnancy. Estetrol acts as an agonist of estrogen receptors (ERα and ERβ), with moderate affinity and selectivity for ERα over ERβ. Its mechanism involves suppression of ovulation through modulation of the hypothalamic-pituitary-gonadal axis. Compared to other estrogens like ethinylestradiol or estradiol, estetrol has lower receptor affinity but higher metabolic stability and favorable pharmacokinetics. It demonstrates high selectivity for estrogen receptors with minimal off-target activity on other steroid hormone receptors or cytochrome P450 enzymes[1][4]. The drug was developed by Mithra Pharmaceuticals and approved in combination products such as Nextstellis (with drospirenone) for contraception[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on estetrol.